Myriad Genetics Presents Additional Flurizan Phase 2 Study Data

Myriad Genetics, Inc. (NASDAQ: MYGN) ( announced today that it presented additional results of its completed Phase 2 follow-on study of Flurizan™ in patients with mild Alzheimer's disease at the annual meeting of the American Association for Geriatric Psychiatry (AAGP), held March 1-4, 2007 in New Orleans.

Read the release in its entirety at
The Alzheimer's Reading Room Weblog